Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-25
2006-07-25
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C544S287000, C544S283000
Reexamination Certificate
active
07081460
ABSTRACT:
The invention is directed to novel quinazoline and quinazoline-like derivatives of Formula (I):useful as integrin antagonists and methods for the treatment of integrin-mediated disorders.
REFERENCES:
patent: 4288362 (1981-09-01), Rolf et al.
patent: 5352667 (1994-10-01), Lider et al.
patent: 5576334 (1996-11-01), Brown et al.
patent: 5602155 (1997-02-01), Ruminski
patent: 5648368 (1997-07-01), Egbertson et al.
patent: 5700801 (1997-12-01), Pieper et al.
patent: 5703050 (1997-12-01), Klingler et al.
patent: 5798370 (1998-08-01), Ruminski
patent: 5817677 (1998-10-01), Linz et al.
patent: 5922717 (1999-07-01), Pieper et al.
patent: 5952381 (1999-09-01), Chen et al.
patent: 6066651 (2000-05-01), Hoekstra
patent: 6069254 (2000-05-01), Contanzo et al.
patent: 6100423 (2000-08-01), Collins et al.
patent: 6251944 (2001-06-01), Chen et al.
patent: 6268380 (2001-07-01), Tjoeng et al.
patent: 6617330 (2003-09-01), Walter
patent: 0373891 (1990-06-01), None
patent: 4334357 (1992-11-01), None
patent: WO 94/12181 (1994-06-01), None
patent: WO 95/08536 (1995-03-01), None
patent: WO 95/32710 (1995-12-01), None
patent: WO 97/06791 (1997-02-01), None
patent: WO 97/08145 (1997-03-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 97/36859 (1997-10-01), None
patent: WO 97/41102 (1997-11-01), None
patent: WO 98/16512 (1998-04-01), None
patent: WO 98/25892 (1998-06-01), None
patent: WO 98/39325 (1998-09-01), None
patent: WO 99/16758 (1999-04-01), None
patent: WO 99/25685 (1999-05-01), None
patent: WO 99/67230 (1999-06-01), None
patent: WO 99/50249 (1999-10-01), None
patent: WO 99/58501 (1999-11-01), None
patent: WO 00/11022 (2000-03-01), None
patent: WO 01/10867 (2001-02-01), None
International Search Report for PCT/US02/10546 dated Apr. 5, 2002.
Biorganic & Medicinal Chemistry Letters, vol. 6, No. 20, pp 2371-2376, 1996-“Solid-Phase Parallel Synthesis Applied to Lead Optimization: Discovery of Potent Analogues of the GPIIb/llla Antagonist RWJ-50042”.
Cox, D., Drug News & Perspectives, 1995, 8, “Integrin antagonists are a new challenge to the pharmaceutical industry and their development will require a multidisciplinary approach, with scientists from different areas working together. Targets in Integrin Research”, pp. 197-205.
Gilon et al., Tetrahedron, 1967, 23, “Synthesis of ω-Aminooxy Acids by Oxygen-Alkyl Fission of Lactones”, pp. 4441-4447.
Greenhill et al., Chem. Soc., Perkin Trans. 2, 1985 (8), “Conformational and Tautomeric Studies of Acylguanidines. Part 1. Synthesis, Utraviolet Spectroscopy, Tautomeric Preference, and Site of Protonation in Some Model Compounds”, pp. 1255-1264.
Hershkovitz et al., Clinical Exp. Immunol. 1994: vol. 95, pp 270-276-“Inhibition of CD4+T lymphocyte binding to fibronection and immune-cell accumulation in imflammatory sites by non-peptidic mimetics of Arg-Gly-Asp”.
Hoekstra, Current Medicinal Chemistry, 1998, 5, “Combinatorial Chemistry Techniques Applied to Nonpeptide Integrin Antagonists”, pp. 195-204.
Hosoda et al., “Preparation of N-(heterocycyclcarbonyl)amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, Chemical Abstracts, vol. 118, No. 25, (1993), XP-002159418.
Keenan et al., Bioorg. Med. Chem. Lett, 1998, 8, “Discovery Of An Imidazopyridine-Containing 1,4-Benzodiazepine Nonpeptide Vitronnectin Receptor (αvβ3) Antagonist With Efficacy In a Restenosis Model”, pp. 3171-3176.
Ludwig et al., J. Med. Chem., 1970, 13, “Synthesis and Hypoglycemic Activity of Substituted Alkyl- and Alkoxyguanidines”, pp. 60-63.
Mehta et al, Biochem J., 1998, 330, “Transmembrance-truncated αvβ3 integrin retains high affinity for ligand binding: evidence for an ‘inside-out’ suppresor?”, pp. 861-869.
Miller et al., Drug Discovery Today, 2000, 5 (9), “Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor)”, pp. 397-408.
Mousa et al., Emerging Theraupeutic Targets, 2000, 4(2), “ Integrins as novel drug-discovery targets: potential therapeutic and diagnostic implications”, pp. 143-153.
Mousa et al., Exp. Opin. Ther. Patents, 1999, 9 (9), “Anti-integrins as a potential therapeutic target in angiogenesis”, pp. 1237-1248.
Rico et al., J. Org. Chem, 1993, 58, “A Highly Stereoselective Michael Addition to an α,β-Unsaturated Ester as the Crucial Step in the Synthesis of a Novel β-Amino Acid-Containing Fibrinogen Receptor Antagionist”, pp. 7948-7951.
Samanen et al., Current Pharmaceutical Design, 1997, 3, “Vascular Indications for Integrin αv Antagonists”, pp. 545-584.
Senanayake et al., Tetrahedron Lett., 1999, 40, “Properly tuned first fluoride-catalyzed TGME-mediated amination process for chloroimidazoles: inexpensive technology for antihistaminic norastemizole” pp. 6875-6879.
Su, Ting, “Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors”, J. Med., Chem. (1997), pp. 4308-4318.
Varon et al., Thromb Haemostasis, 1993, 70(6), “Inhibition of Integrin-Mediated Platelet Aggregation Fibrinogen-Binding, and Interactions with Extracellular Matrix by Nonpeptidic Mimetics of Arg-Gly-Asp”, pp. 1030-1036.
Archelos, J.J., et al., “The role of integrins in immune-mediated diseases of the nervous system”, TNS, vol. 22, No. 1, 1999, pp. 30-38.
Cotman, C.W.. et al., “Cell Adhesion Molecules in Neural Plasticity and Pathology: Similar Mechanisms, Distinct Organizations?”, Progress in Neurobiology, vol. 55, 1998, pp. 659-669.
Milner, R., “Understanding the molecular basis of cell migration; implications for clinical therapy in multiple sclerosis”, Clinical Science, (1997) 92, pp. 113-122.
Fossati, G., et al., “In vitro effects of GM-CSF on mature peripheral blood neutrophils”, International Journal of Molecular Medicine 1, 1998, pp. 943-951.
Hynes, R.O., “Integrins: Versatility, Modulation, and Signaling in Cell Adhesion”, Cell, vol. 69, Apr. 3, 1992, pp. 11-25.
Lee, J., et al., Crystal Structure of the A Domain form the α Subunit of Integrin CR3 (CD11b/CD18); Cell, vol. 80, Feb. 24, 1995, pp. 631-638.
McCoy, L.E., “Basic Concepts of Hemostasis and thrombosis: Clinical and Laboratory Evaluation of Thrombohemorrhagic Phenomena”, Murano, G., Bick, R.L. Eds.; CRC: Boca Raton, Florida, 1980, pp. 5-15.
Hughes, P.E., et al., “Integrin affinity modulation”, Trends in Cell Biology, 1998, vol. 8, pp. 359-364.
Clover, J., et al., “Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture” Journal of Cell Science, 103, pp. 267-271.
Duggan, M.E., et al., “Nonpeptide of αvβ3Antagonists 1 . Transformation of a Potent, Integrin-Selective αllbβ3Antagonist into a Potent αvβ3Antagonist”, J. Med. Chem, 2000, 43, pp. 3736-3745.
Attur, Mukundan G., “Functional Genomic Analysis in Arthritis-Affected Cartilage: Yin-Yang Regulation of Inflammatory Mediators by α5β1and αvβ3Integrins”, The Journal of Immunogoly, Copyright 2000 by The american Association of Immunologists, pp. 2684-2691.
Buckley, C.D., “Identification of αvβ3as a heterotypic ligand for CD31/PECAM-1”, Journal of Cell Science, 109, 1996, pp. 437-445.
Scaffidi, Amelia K., “Regulation of human lung fibroblast phenotype and function by vitronectin and vitronectin integrins”, Journal of Cell Science, 114, 2001, pp. 3507-3516.
Fields, Gregg B., “Integrins: cell adhesion molecules in cancer”, Exp. Opin. Ther. Patents (1998), 8(6), pp. 633-644.
Byzova, Tatiana V., et al., “Role of Integrin αvβ3in Vascular Biology”, Thromb. Haemost, (1998), 80, pp. 726-734.
Larksarp, Chitchamai et al., “Palladium-Catalyzed Cyclocarbonylation of
Costanzo Michael J.
Hoekstra William J.
Lawson Edward C.
Balasubramanian Venkataraman
Ortho-McNeil Pharmaceutical , Inc.
Woodrow Hal B.
LandOfFree
Quinazoline and quinazoline-like compounds for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline and quinazoline-like compounds for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline and quinazoline-like compounds for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3591546